Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02903277 | National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent | withdrawn | — | 0 | Centre Hospitalier Universitaire de NiceOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Jun 15, 2026 |
| NCT03688789 | Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology(HemaSur) | withdrawn | N/A | 0 | Rennes University HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial(ROMECO) | withdrawn | N/A | 0 | University Hospital, ToursOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 2 | Jun 10, 2026 | clinicaltrials |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type(CYNK001GBM02) | withdrawn | Phase 1 / Phase 2 | 0 | Celularity IncorporatedINDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT05538689 | Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)(SOUL) | withdrawn | Phase 4 | 0 | University of ChicagoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05312476 | Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07123662 | γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant | withdrawn | Early Phase 1 | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT07195617 | Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment(r/r MM) | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides(Resimmune®) | withdrawn | Phase 2 | 0 | Virogen Biotechnology Inc.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT06522373 | Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06660121 | Electrochemotherapy for Desmoid Tumors(ECT-DESMO) | withdrawn | — | 0 | Istituto Ortopedico RizzoliOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT06698744 | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | David WaldOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study | withdrawn | Early Phase 1 | 0 | Kousai Bio Co., Ltd.OTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 8, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT07093086 | Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07453446 | Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma | withdrawn | Phase 1 | 0 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT07134556 | Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC(ADJUNCT) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT05846737 | BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06732258 | Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC | withdrawn | Phase 1 | 0 | Sichuan UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT06769555 | BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy | withdrawn | N/A | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | withdrawn | Early Phase 1 | 0 | Thomas HopeOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies | withdrawn | — | 0 | IpsenINDUSTRY | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553520 | Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients | withdrawn | N/A | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02633514 | Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma | withdrawn | Phase 3 | 0 | Fudan UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | withdrawn | Phase 2 | 0 | Douglas JohnsonOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07092410 | Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib(SuRage-EB) | withdrawn | Phase 4 | 0 | SRH Wald-Klinikum Gera GmbHOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Eli Avisar, MDOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | withdrawn | N/A | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06767956 | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT06434103 | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | withdrawn | Phase 1 / Phase 2 | 0 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 8, 2026 | clinicaltrials |
| NCT07030699 | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma(ECLAT) | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | withdrawn | Phase 2 | 0 | NGM Biopharmaceuticals, IncINDUSTRY | 0 | Apr 6, 2026 | clinicaltrials |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | withdrawn | Phase 2 | 0 | Eric Jacobsen, MDOTHER | 0 | Apr 1, 2026 | clinicaltrials |
| NCT07049432 | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas(CARMEN-803) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02450396 | Pregnancy and Medically Assisted Conception in Rare Diseases(EGR2) | withdrawn | — | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | withdrawn | — | 0 | Methodist Health SystemOTHER | 0 | Mar 23, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 16, 2026source: clinicaltrials